Treatment resistance may be the result of a mutation

WHY YOUR TREATMENT MAY STOP WORKING

The goal of treating chronic myeloid leukemia (CML) is to reduce levels of BCR-ABL1 and keep them low. BCR-ABL1 is the protein created by the mutated BCR-ABL gene that leads to the creation of leukemia cells. You and your healthcare provider should be monitoring your BCR-ABL1 levels every 3, 6, and 12 months when you're on treatment. Sometimes, medications start to lose their effectiveness over time. If you see your BCR-ABL1 levels rise, this may be due to treatment resistance.

WHY DOES CML BECOME RESISTANT TO A PARTICULAR TREATMENT?

One reason may be that over time, your CML has developed a mutation. A mutation is a change in a gene. For CML, it is a change in the BCR-ABL gene. This may cause a particular treatment to stop working.

GETTING A MUTATION TEST

Your healthcare provider can order a lab test to help determine whether your CML has developed a mutation. The test looks for mutations in the BCR-ABL gene. In many cases, it can be performed at the same facility where you've had other tests. **Talk to your healthcare provider about whether mutation testing is appropriate for you.** If your healthcare provider decides to test for a mutation, be sure to follow up with them to discuss the results. Keep in mind that more than one test may be needed to determine whether you have a mutation.

MUTATION TESTING CAN HELP GUIDE TREATMENT DECISIONS

The word "mutation" may sound scary. However, knowing whether your CML has developed a mutation can be critical in determining your next treatment option. **Today, there are treatments that work against CML with specific mutations. Knowing your mutation status may give you and your healthcare provider a powerful tool to help continue to control your CML.**

THE T315I MUTATION

One common mutation is the **T315I mutation**. **Talk to your healthcare provider about whether your mutation test shows the T315I mutation.** There are specific treatments that can be used against CML with the T315I mutation.

Talk to your healthcare provider about mutation testing

Download our Doctor Discussion Guide at CMLtreatment.com
or scan the code below to help get the conversation started.

Learn more about a treatment for CML at CMLtreatment.com, or scan this code.

© 2022 Takeda Pharmaceuticals U.S.A., Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. All rights reserved. USO-NON-0452 03/22